SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (10106)5/19/1999 9:12:00 PM
From: Robert K.  Respond to of 17367
 
George, I do not disagree with you at all that price does not matter.
It does matter very much, ultimately our fate rests with the molecule.
Additionally the company must weigh disclosure vs secrecy. Secrecy has its pro's and cons(stock price). I am still thinking angioprex is a cool name. Doesnt it make you wonder why xoma says almost nothing about its angio program, while the entremeds et al... beat the drums. Standard K disclaimer.
BTW-angioprex is nothing but a guess of mine.



To: aknahow who wrote (10106)5/20/1999 7:42:00 AM
From: Tharos  Respond to of 17367
 
George,
It's good to see the stock back over $5 again. This means the "main street" brokerage firms can recommend the stock to their clients/customers. This does not imply they will, just that they can.

Usual disclaimers about stock investing, hair loss, and life after death + whatever RobertK says.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News